Theravance Biopharma, Inc.
DE ˙ DB ˙ KYG8807B1068
13,60 € ↑0,30 (2,26%)
2026-06-04
AKTIENPREIS
SecurityDE:0TB / Theravance Biopharma, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership3,402,767 shares
Ownership 5.05%
Barclays Plc ownership in 0TB / Theravance Biopharma, Inc.

2023-01-30 - Barclays Plc has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,402,767 shares of Theravance Biopharma, Inc. (DE:0TB). This represents 5.05 percent ownership of the company.

Barclays Plc has a history of taking positions in derivatives of the underlying security (0TB) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2023-01-30 2023-01-30 13G 3,402,767 5.05

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:0TB / Theravance Biopharma, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 111,619 -3,772 -3.27 2,088 23.99 0.0005
2026-03-31 2025-09-30 13F/A-3 THERAVANCE BIOPHARMA COM G8807B106 115,391 -16,411 -12.45 1,685 15.90 0.0004
2026-03-19 2025-09-30 13F/A-2 THERAVANCE BIOPHARMA COM G8807B106 65,580 -66,222 529 0.0001
2025-11-12 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 115,391 -16,411 1,685 0.0004
2026-02-27 2025-06-30 13F/A-2 THERAVANCE BIOPHARMA COM G8807B106 131,802 79,769 153.30 1,454 213.15 0.0003
2025-08-14 2025-06-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 131,802 79,769 1 0.0003
2025-08-13 2025-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 131,802 79,769 1 0.0001
2026-03-17 2025-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 52,033 -22,757 -30.43 465 -34.00 0.0001
2025-05-15 2025-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 52,033 -22,757 0 0.0001
2026-03-19 2024-12-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 74,790 9,210 14.04 704 33.14 0.0002
2025-02-13 2024-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 74,790 9,210 1 0.0002
2026-03-31 2024-09-30 13F/A-2 THERAVANCE BIOPHARMA COM G8807B106 65,580 48,316 279.87 529 261.64 0.0001
2024-11-19 2024-09-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 65,580 48,316 1 0.0001
2024-11-15 2024-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 65,580 48,316 1 0.0001
2026-03-23 2024-06-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 17,264 -27,747 -61.64 146 -63.77 0.0000
2024-08-14 2024-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 17,264 -27,747 0 0.0000
2026-03-24 2024-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 45,011 -37,346 -45.35 404 -56.43 0.0001
2024-05-15 2024-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 45,011 -37,346 0 0.0001
2026-03-25 2023-12-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 82,357 59,088 253.93 926 362.50 0.0003
2024-02-15 2023-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 82,357 59,088 1 0.0003
2026-03-26 2023-09-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 23,269 -5,554 -19.27 201 -32.89 0.0001
2023-11-07 2023-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 23,269 -5,554 0 0.0001
2026-03-30 2023-06-30 13F/A-2 THERAVANCE BIOPHARMA COM G8807B106 28,823 -7,779 -21.25 298 -24.94 0.0002
2023-09-20 2023-06-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 28,823 -7,779 0 0.0002
2023-08-03 2023-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 28,823 -7,779 0 0.0002
2026-03-30 2023-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 36,602 12,979 54.94 397 49.81 0.0002
2023-05-04 2023-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 36,602 12,979 0 0.0002
2026-03-30 2022-12-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 23,623 12,425 110.96 265 132.46 0.0001
2023-02-13 2022-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 23,623 12,425 0 0.0001
2022-11-03 2022-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 11,198 -9,769 -46.59 114 -40.00 0.0001
2022-08-12 2022-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 20,967 -7,657 -26.75 190 -30.66 0.0001
2022-05-16 2022-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 28,624 -65,785 -69.68 274 -73.75 0.0002
2022-02-23 2021-12-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 94,409 35,619 60.59 1,044 140.00 0.0004
2022-02-14 2021-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 94,409 35,619 1,044 0.0001
2021-11-09 2021-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 58,790 51,922 756.00 435 335.00 0.0002
2021-08-13 2021-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 6,868 -44,452 -86.62 100 -90.45 0.0000
2021-05-13 2021-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 51,320 25,216 96.60 1,047 125.65 0.0006
2021-02-11 2020-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 26,104 -17,016 -39.46 464 -27.16 0.0002
2020-11-12 2020-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 43,120 -28,124 -39.48 637 -57.39 0.0004
2020-08-12 2020-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 71,244 27,721 63.69 1,495 48.76 0.0012
2020-05-13 2020-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 43,523 -11,185 -20.44 1,005 -29.03 0.0008
2020-02-10 2019-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 54,708 9,628 21.36 1,416 61.09 0.0008
2019-11-15 2019-09-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 45,080 -65,159 -59.11 879 -51.17 0.0005
2019-11-14 2019-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 45,080 -65,159 879 203.2258
2019-08-14 2019-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 110,239 66,146 150.01 1,800 80.00 0.0011
2019-05-15 2019-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 44,093 25,341 135.14 1,000 107.90 0.0007
2019-02-14 2018-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 18,752 -12,734 -40.44 481 -53.26 0.0004
2018-11-14 2018-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 31,486 28,347 903.06 1,029 1,329.17 0.0007
2018-08-14 2018-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 3,139 -8,686 -73.45 72 -74.83 0.0001
2018-05-15 2018-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 11,825 2,933 32.98 286 15.32 0.0002
2018-02-14 2017-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 8,892 6,562 281.63 248 213.92 0.0002
2017-11-14 2017-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 2,330 563 31.86 79 11.27 0.0001
2017-08-14 2017-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,767 -14,708 -89.27 71 -88.30 0.0001
2017-05-15 2017-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 16,475 12,857 355.36 607 427.83 0.0007
2017-02-14 2016-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 3,618 1,692 87.85 115 61.97 0.0001
2016-11-14 2016-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,926 -11,563 -85.72 71 -76.72 0.0001
2016-08-12 2016-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 13,489 13,106 3,421.93 305 4,257.14 0.0004
2016-05-16 2016-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 383 -6,667 -94.57 7 -93.81 0.0000
2016-02-12 2015-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 7,050 -2,007 -22.16 113 25.56 0.0001
2015-11-13 2015-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 9,057 8,486 1,486.16 90 1,185.71 0.0001
2015-08-14 2015-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 571 -567 -49.82 7 -63.16 0.0000
2015-05-19 2015-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 1,138 -3,018 -72.62 19 -67.80 0.0000
2015-05-14 2015-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 1,138 19
2015-02-13 2014-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 4,156 724 21.10 59 -26.25 0.0001
2014-11-14 2014-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 3,432 -3,641 -51.48 80 -63.64 0.0001
2014-08-14 2014-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 7,073 7,073 220 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2018-11-14 2018-09-30 13F THERAVANCE BIOPHARMA OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-08-14 2018-06-30 13F THERAVANCE BIOPHARMA OPT Call 95,000 0.00 2,155 -6.47 n/a n/a n/a
2018-05-15 2018-03-31 13F THERAVANCE BIOPHARMA OPT Call 95,000 2,304 n/a n/a n/a
2015-05-14 2015-03-31 13F THERAVANCE BIOPHARMA OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-02-13 2014-12-31 13F THERAVANCE BIOPHARMA OPT Call 1,036 -9.76 15 -42.31 n/a n/a n/a
2014-11-14 2014-09-30 13F THERAVANCE BIOPHARMA OPT Call 1,148 -37.88 26 -55.17 n/a n/a n/a
2014-08-14 2014-06-30 13F THERAVANCE BIOPHARMA OPT Call 1,848 58 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2015-05-14 2015-03-31 13F THERAVANCE BIOPHARMA OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2015-02-13 2014-12-31 13F THERAVANCE BIOPHARMA OPT Put 112 0.00 2 -33.33 n/a n/a n/a
2014-11-14 2014-09-30 13F THERAVANCE BIOPHARMA OPT Put 112 -50.00 3 -57.14 n/a n/a n/a
2014-08-14 2014-06-30 13F THERAVANCE BIOPHARMA OPT Put 224 7 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.